# Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

> **NCT01807221** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 1066 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Finerenone (BAY94-8862)
- **DRUG:** Placebo
- **DRUG:** Inspra (eplerenone)

## Key facts

- **NCT ID:** NCT01807221
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-17
- **Primary completion:** 2014-11-11
- **Final completion:** 2014-12-09
- **Target enrollment:** 1066 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01807221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01807221, "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01807221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*